Format

Send to

Choose Destination
Br J Clin Pharmacol. 2019 Apr;85(4):729-736. doi: 10.1111/bcp.13847. Epub 2019 Feb 3.

Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler.

Author information

1
Medicines Evaluation Unit, University of Manchester, Manchester, UK.
2
Hammersmith Medicines Research ltd, London, UK.
3
Respiratory Clinical Trials ltd, London, UK.
4
Department of Medicine and Surgery, University of Parma, Parma, Italy.
5
Scottish Centre for Respiratory Research, Dundee, UK.
6
Chiesi Farmaceutici SpA, Parma, Italy.

Abstract

AIMS:

To demonstrate the noninferiority of extrafine beclomethasone/formoterol fumarate (BDP/FF) dry powder inhaler (DPI) vs. extrafine BDP/FF pressurized metered dose inhaler (pMDI; Foster® 100/6 μg NEXThaler and pMDI, respectively) in the onset of reliever effect after methacholine induced bronchospasm in asthmatic patients, evaluated in terms of forced expiratory volume in 1 s (FEV1 ) at 5 min postdose. The DPI provides an alternative device option for patients who cannot use a pMDI properly during an acute asthma attack.

METHODS:

Sixty-five patients received one inhalation of BDP/FF DPI, BDP/FF pMDI or placebo after methacholine challenge, according to a double-blind, double-dummy, cross-over design. Lung function and Borg dyspnoea score were assessed up to 30 min postdose.

RESULTS:

FEV1 adjusted mean difference between BDP/FF DPI and BDP/FF pMDI at 5 min postdose was 2 ml (95% confidence interval: -0.060; 0.065). A similar result was observed at the other time points. Median time to 85% recovery in FEV1 was 8 min for BDP/FF DPI, 7.5 min for BDP/FF pMDI and 28 min for placebo (P = 0.554 DPI vs. pMDI). The Borg score improved after treatment with both BDP/FF DPI and pMDI and the effect was greater than after placebo. Median time to reach 50% recovery was 4.2 min for BDP/FF DPI, 4.0 min for BDP/FF pMDI and 10.0 min for placebo (P = 0.609 DPI vs. pMDI).

CONCLUSIONS:

Extrafine Foster® NEXThaler, a flow-independent DPI, is comparable to extrafine Foster® pMDI when administered as reliever therapy after methacholine challenge, thus supporting the maintenance and reliever therapy approach also with Foster® NEXThaler.

KEYWORDS:

Clinical Trials; asthma; inhalation

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center